ExonHit Therapeutics S.A. 65 Boulevard Mass na F-75013 Paris France Phone: +33-1-53-94-77-00 Fax: +33-1-53-94-77-07 www.exonhit.com Management Bruno Tocque, CEO Florence Abrahamian, chief financial officer Laurent Bracco, vice president of research, technology Fabien Schweighoffer, vice president of research, therapeutic programs Jim Lyddy, vice president, international business development Aram Mangasarian, director, business development Overview ExonHit Therapeutics S

Epigenomics GmbH Kastanienallee 24 D-10435 Berlin Germany Phone: +49 30 24 34 50 Fax: +49 30 24 34 55 55 www.epigenomics.com Management Alexander Olek, CEO Oliver Schacht, chief financial officer Christian Piepenbrock, chief information officer Kurt Berlin, chief scientific officer Aron Braun, chief technology officer Overview Epigenomics AG, a Berlin-based start-up, analyzes the complexity of cellular activities by measuring the methylation patterns of DNA. While

Eos Biotechnology Inc. 225A Gateway Blvd. South San Francisco, CA 94080 Phone: (650) 246-2300 Fax: (650) 583-3881 www.eosbiotech.com Management David Martin, president and CEO Herbert Heyneker, chief technical officer David Mack, vice president, genomics research Richard Murray, vice president, biological research John Whelan, chief financial officer Overview Eos Biotechnology Inc., based in South San Francisco, has designed and built a platform of integrated genomic-based

Cogent Neuroscience Inc. 4425 Ben Franklin Blvd. Durham, NC 27704 Phone: (919) 688-7100 Fax: (919) 688-7156 www.cogentneuroscience.com Management Max Wallace, president and CEO Donald Lo, chief scientific officer Matthew McDonald, chief financial officer Shawn Barney, vice president, discovery David LaVance, vice president, business development Overview Cogent Neuroscience was founded in 1998 by Duke University researchers Lawrence Katz and Donald Lo, who - together with

Elitra Pharmaceuticals Inc. 3510 Dunhill Street San Diego, CA 92121 Phone: (858) 410-3030 Fax: (858) 410-3810 www.elitra.com Management Harry Hixson, CEO, president and chairman of the board Gordon Foulkes, executive vice president of research and development Alana McNulty, vice president of finance and chief financial officer Edgardo Baracchini, vice president, business development Judith Zyskind, founder and member of board of directors Overview Elitra Pharmaceuticals

DoubleTwist Inc. 2001 Broadway Oakland, CA 94612 Phone (510) 628-0100 Fax (510) 628-0108 www.doubletwist.com Management John Couch, president and CEO Robert Williamson, chief operating officer Ward Wolff, chief financial officer Douglas Brutlag, chief scientific officer Stephen Sanders, vice president of worldwide sales Overview Although originally founded in 1993 as Pangea Systems Inc., a direction shift in 1999 brought DoubleTwist s focus to genomics. As Pangea Systems

Digital Gene Technologies Inc. 11149 North Torrey Pines Road La Jolla, California 92037 Phone: (858) 552-1400 Fax: (858) 552-8625 www.dgt.com Management Robert J. Sutcliffe, president and CEO J. Gregor Sutcliffe, chairman, scientific advisory board Thomas E. Griffin, chief financial officer Brian S. Hilbush, vice president of discovery biology David D. Lo, vice president of integrative biology Richard W. Keatinge, vice president, business development Christina Madrid, director

Devgen N.V. Technologiepark 9 9052 Zwijnaarde Ghent, Belgium Phone: 32 9 324 24 24 Fax: 32 9 324 24 25 www.devgen.com Management Thierry Bogaert, CEO Hilde Windels, chief financial officer Robin Brown, chief scientific officer Ben Tan, executive vice president, business Overview Devgen N.V., based in Ghent, Belgium, was founded in December 1997 as a drug and target discovery company. It industrializes the model organism C. elegans to accelerate discovery of relevant drug

Atugen AG Robert-R ssle-Strasse 10 13125 Berlin Germany Phone: +49 30 94 89 27 00 2950 Wilderness Place Boulder, CO 80301 Phone: (303) 449-6500 www.atugen.com Management Rudi Neirinckx, CEO, president and chairman Klaus Giese, vice president for research J rg P tzsch, vice president of administration Zisi Fotev, vice president, business development David Traylor, director of USA operations Overview Atugen AG was formed in 1998 as a spin-out of the target discovery and

Arcaris Inc. 615 Arapeen Drive, Suite 300 Salt Lake City, UT 84108 Phone: (801) 303-0300 www.arcaris.com Management C. Alexander Kamb, president, CEO and chief scientific officer Overview Arcaris Inc., formerly called Ventana Genetics, was founded in May 1996 in Salt Lake City to discover drug targets based on their biological activity in human cell assays. These function-based assays use perturbagens expressed peptides or small protein fragments to disrupt the physiological

Artemis Pharmaceuticals GmbH Neurather Ring 1 51063 K ln Germany Phone: +49 (0) 221-96453-10 Fax: +49 (0) 221-96453-21 www.artemis-pharmaceuticals.de Management Peter Stadler, CEO Paul Rounding, head of business development Overview Artemis Pharmaceuticals GmbH, a biotechnology company with headquarters in Cologne, Germany, and research facilities in both Cologne and T bingen, Germany, was founded in June 1998. Artemis has a strategic alliance with its sister company

Anadys Pharmaceuticals Inc. 9050 Camino Santa Fe San Diego, CA 92121 Telephone: (858) 530-3600 Fax: (858) 527-1540 www.anadyspharma.com Management Kleanthis Xanthopoulos, president and CEO Devron Averett, senior vice president of research, development and medical Alexander Chucholowski, senior director of chemistry Cheryl Lawton, general counsel and senior vice president Lisa Potok, director of finance David Nelson, associate director of corporate development and strategy

AlphaGene Inc. 10 Cedar Street Woburn, MA 01801 Phone: (781) 933-4446 Fax: (781) 938-7922 www.alphagene.com Management Donald McCarren, president and CEO Peter Schad, chief scientific officer Peter White, chief financial officer William Hough, vice president, business development Overview AlphaGene is a privately held, functional genomics company that boasts a physical inventory of approximately 350,000 human clones isolated from cDNA libraries constructed using its

Acadia Pharmaceuticals Inc. 3911 Sorrento Valley Blvd. San Diego, CA 92121 Phone: (858) 558-2871 Fax: (858) 558-2872 www.acadia-pharm.com Management Uli Hacksell, CEO Mark Brann, president, chief scientific officer and founder Thomas Aasen, vice president and chief financial officer Overview Acadia Pharmaceuticals Inc. is headquartered in San Diego and has laboratories in both San Diego and Copenhagen, Denmark. It was founded in 1993 as Receptor Technologies Inc. Acadia is

Genome Therapeutics Corp. 100 Beaver Street Waltham, MA 02453-8443 Phone: (781) 398-2300 Fax: (781) 893-8277 www.genomecorp.com Management Steven Rauscher, president and CEO Philip Holberton, chief financial officer Christopher Kelly, senior vice president, general manager, Drug Rescue business Richard Labaudiniere, senior vice president, research and development Lynn Doucette-Stamm, vice president and general manager, GTC Sequencing business Andrew DePristo, vice president

Gene Logic Inc. 708 Quince Orchard Road Gaithersburg, MD 20878 Phone: (301) 987-1700 Fax: (301) 987-1701 www.genelogic.com Management Michael Brennan, chairman Mark Gessler, president, CEO and director Philip Rohrer, chief financial officer David Murray, senior vice president, marketing and sales Victor Markowitz, senior vice president, chief technology officer Eric Eastman, senior vice president, chief information officer Douglas Dolginow, senior vice president

Genaissance Pharmaceuticals Inc. Five Science Park New Haven, CT 06511 Phone: (203) 773-1450 Toll Free: (877) 476-4363 Fax: (203) 562-9377 www.genaissance.com Management Jurgen Drews, chair of board of directors Gualberto Ruano, CEO Kevin Rakin, president and chief financial officer Kenneth Kashkin, executive vice president and chief medical officer Gerald Vovis, senior vice president and chief technology officer Richard Judson, senior vice president, informatics Krishnan

Gemini Genomics plc 162 Science Park Milton Road Cambridge CB4 0GH UK Tel: +44 (0) 12 23 43 5300 Fax: +44 (0) 12 23 43 5301 www.gemini-genomics.com Management Paul Kelly, president and CEO Tony Ratcliff, chief financial officer Zahed Subhan, chief business officer Howard Christley, chief medical officer Patrick Kleyn, chief scientific officer Roger Dickinson, group company secretary and general counsel Overview Gemini Genomics plc, a clinical genetics company

Exelixis Pharmaceuticals Inc. 170 Harbor Way P.O. Box 511 South San Francisco, CA 94083 Phone: (650) 837-7000 Fax: (650) 837-8205 www.exelixis.com Management George Scangos, president and CEO Geoffrey Duyk, chief scientific officer Lloyd Kunimoto, senior vice president, corporate development Glen Sato, chief financial officer and vice president, legal affairs Christian Burks, vice president and chief informatics officer Michael Morrissey, vice president of discovery research